Lung Cancer Screening Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Lung Cancer Screening Market: By Cancer Type (Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer), By Diagnosis Type (Low Dose Spiral CT scan, And Chest X-Ray), by End-Users (Hospital & Clinics and Diagnostic Centers) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Lung Cancer Screening Market size was valued at USD 1,768.1 million in 2021, growing at a significant CAGR of 6.5% over 2022-2028. A type of disease that occurs in the lungs is known as lung cancer. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the 2 main types of lung cancer and are treated differently. The non-small cell lung cancer segment anticipated to grow at significant CAGR over the forecast years owing to non-small cell lung cancer are the most common type of cancer accounted for approximate 85% of all lung cancers. However, non-Small cell Lung cancer metastasizes to other organ  slower in compression to SCLC, and microscopically , SCLC is composed of much smaller cells. if untreated, SCLC can be fatal in few weeks, in contrast to most cases of NSCLC. Moreover, as per the research Non–small cell lung cancer accounts for 85% of all lung cancer cases in the United States after the initial diagnosis.  The prevalence of lung cancer cases worldwide, greater emphasis on technological developments in the production of medical devices, and rising spending on the expansion of healthcare infrastructure, particularly in developing economies, are the main drivers of the lung cancer screening market.

Lung Cancer Screening Market

MARKET SUMMARY
-
6.5%
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 6.5%
  • Largest Market– Asia Pacific
  • Fastest Growing Market–  North America

Lung Cancer Screening Market

  • The global lung cancer screening market report gives comprehensive outlook on bovine respiratory disease treatment across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The lung cancer screening market report gives historical, current, and future market sizes (US$ Mn) on the basis of by cancer type, by diagnosis type, end-users, and geography.
Key Players
  • PenRad Technologies Inc.
  • Koninklijke Philips N.V
  • Volpara Health Limited
  • Nuance Communications, Inc.
  • Siemens Healthcare GmbH
Lung Cancer Screening Market Dynamics

The lung cancer screening market is anticipated to grow in the forecasting period owing to surge in the incidence of the type of cancer due to increase smoking population, technology advancement in screening, and increasing in government support of early detection of cases. Moreover, other player is focusing on strategy and collaboration are also likely to boost the market growth in the near future. For instance, In September 2021Genentech and Roche are actively exploring the development of biomarker to test lung cancer and detection.


North-America Got Significant Share

Lung Cancer Screening Market

The North America is likely to hold the highest revenue share of in 2021 and same trend is expected over the forecast period due to ageing population and increased lung cancer incidence. Moreover, North America is regarded as the largest regional market with the highest market share due to increased market invasion rates of technologically advanced products, rising patient awareness, and rising smoking prevalence levels in the region, all of which contribute to the region's largest market share.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Lung Cancer Screening Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The lung cancer screening market growing at a CAGR of 6.5% during 2022

PenRad Technologies Inc., Koninklijke Philips N.V, Volpara Health Limited, Thynk Health, Nuance Communications, Inc., Siemens Healthcare GmbH

North America is the fastest-growing region for lung cancer screening market


Report

Company Profile

  • PenRad Technologies Inc.
  • Koninklijke Philips N.V
  • Volpara Health Limited
  • Thynk Health
  • Nuance Communications, Inc.
  • Siemens Healthcare GmbH
  • MyCareWare, Inc.
  • MagView
  • MeVis Medical Solutions AG
  • Canon Medical Informatics, Inc.
  • General Electric Company
  • Epic Systems Corporation
  • Lungview
  • Eon
  • Medtronic
  • HealthMyne
  • Oncocyte Corporation
  • Genesystem
  • FUJIFILM Holdings Corporation
  • Median Technologies
  • AstraZeneca

Description

Lung Cancer Screening Market size was valued at USD 1,768.1 million in 2021, growing at a significant CAGR of 6.5% over 2022-2028. A type of disease that occurs in the lungs is known as lung cancer. Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the 2 main types of lung cancer and are treated differently. The non-small cell lung cancer segment anticipated to grow at significant CAGR over the forecast years owing to non-small cell lung cancer are the most common type of cancer accounted for approximate 85% of all lung cancers. However, non-Small cell Lung cancer metastasizes to other organ  slower in compression to SCLC, and microscopically , SCLC is composed of much smaller cells. if untreated, SCLC can be fatal in few weeks, in contrast to most cases of NSCLC. Moreover, as per the research Non–small cell lung cancer accounts for 85% of all lung cancer cases in the United States after the initial diagnosis.  The prevalence of lung cancer cases worldwide, greater emphasis on technological developments in the production of medical devices, and rising spending on the expansion of healthcare infrastructure, particularly in developing economies, are the main drivers of the lung cancer screening market.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX